Skip Navigation



Annals of Oncology Advance Access published online on May 13, 2005
Annals of Oncology, doi:10.1093/annonc/mdi212
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/7/1140    most recent
mdi212v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aschele, C.
Right arrow Articles by Monfardini, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aschele, C.
Right arrow Articles by Monfardini, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received October 14, 2004
Revised January 29, 2005
Accepted February 7, 2005

Original article

A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer

C. Aschele 1*, M. L. Friso 2, S. Pucciarelli 3, S. Lonardi 4, L. Sartor 4, G. Fabris 3, E. D. L. Urso 3, P. Del Bianco 5, G. Sotti 2, M. Lise 3, and S. Monfardini 4

1 Department of Medical Oncology and Cancer Prevention, E. O. Ospedali Galliera, Genova, Italy
2 Radiotherapy and, Padova University Hospital, Padova
3 Surgery, Padova University Hospital, Padova
4 Departments of Medical Oncology, Padova University Hospital, Padova
5 Clinical Epidemiology Unit, Regional Cancer Centre, Padova University Hospital, Padova

* To whom correspondence should be addressed.
C. Aschele, E-mail: aschele{at}tin.it


  Abstract

Background: Oxaliplatin (OXA) significantly enhanced the antitumour activity of 5-fluorouracil (FUra) in patients with advanced colorectal cancer and displayed radiosensitising properties in preclinical studies. This study was thus performed to test the feasibility, identify the recommended doses (RDs) and explore preliminarily the clinical activity of weekly OXA and infused FUra combined with preoperative pelvic radiotherapy.

Patients and methods: Forty-six patients with recurrent or locally advanced (cT3-4 and/or N+) adenocarcinomas of the mid-low rectum were treated with escalating doses of OXA (25, 35, 45, 60 mg/m2, weekly for 6 weeks) and FUra (200-225 mg/m2/day, 6-week infusion) concurrent to preoperative pelvic radiotherapy (50.4 Gy/28 fractions). The RDs for the phase II part of the study were immediately below the level resulting in dose-limiting toxicities in more than one third of the patients, or corresponded to the last planned dose level.

Results: In the escalation phase, dose-limiting toxicities only occurred in one patient at the fourth level and one of six patients treated at the last planned dose level (grade III diarrhoea). OXA 60 mg/m2 and FUra 225 mg/m2/day are therefore the RDs for the regimen. Among 25 patients globally treated at these doses (phase II part), the incidence of grade III diarrhoea was 16% with no grade IV toxicity. Neurotoxicity did not exceed grade II (12%). All patients completed radiotherapy and were operated on as scheduled. Twenty-one of 25 patients had the tumour down-staged after chemoradiation with seven (28%) pathological complete responses and 12 (48%) residual tumours limited to ypT1-2N0.

Conclusions: Weekly OXA, at doses potentially active systemically, can be combined with full-dose, infused FUra and radiotherapy. Given the low toxicity and promising activity, this regimen is being compared to standard FUra-based pelvic chemoradiation in a randomised study.

Keywords: 5-fluorouracil; neoadjuvant chemoradiation; oxaliplatin; phase I-II study; rectal cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. Moureau-Zabotto, J.-M. Phelip, P. Afchain, L. Mineur, T. Andre, V. Vendrely, G. Lledo, O. Dupuis, F. Huguet, E. Touboul, et al.
Concomitant Administration of Weekly Oxaliplatin, Fluorouracil Continuous Infusion, and Radiotherapy After 2 Months of Gemcitabine and Oxaliplatin Induction in Patients With Locally Advanced Pancreatic Cancer: A Groupe Coordinateur Multidisciplinaire en Oncologie Phase II Study
J. Clin. Oncol., March 1, 2008; 26(7): 1080 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
C. Rodel
Radiation Therapy Combined with Novel Chemotherapy Regiments and Targeted Agents for Patients with Rectal Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 146 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Willett, B. G. Czito, and J. C. Bendell
Radiation Therapy in Stage II and III Rectal Cancer
Clin. Cancer Res., November 15, 2007; 13(22): 6903s - 6908s.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Aschele and S. Lonardi
Multidisciplinary treatment of rectal cancer: medical oncology.
Ann. Onc., November 1, 2007; 18(11): 1908 - 1915.
[Full Text] [PDF]

Home page
 JCOHome page
R. A. Sharma, G. A. Van Hazel, B. Morgan, D. P. Berry, K. Blanshard, D. Price, G. Bower, J. A. Shannon, P. Gibbs, and W. P. Steward
Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin Chemotherapy
J. Clin. Oncol., March 20, 2007; 25(9): 1099 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Aschele and S. Lonardi
Addition of Weekly Oxaliplatin to Standard Preoperative Chemoradiation for Locally Advanced Rectal Cancer
J. Clin. Oncol., February 10, 2007; 25(5): 602 - 603.
[Full Text] [PDF]

Home page
 JCOHome page
D. P. Ryan, D. Niedzwiecki, D. Hollis, J. Tepper, and R. J. Mayer
In Reply
J. Clin. Oncol., February 10, 2007; 25(5): 603 - 603.
[Full Text] [PDF]

Home page
 Ann OncolHome page
T. Watanabe, T. Kiyomatsu, T. Kanazawa, Y. Kazama, T. Kojima, J. Tanaka, T. Tanaka, and H. Nagawa
Weekly oxaliplatin and preoperative radiotherapy as a new neoadjuvant therapy for locally-advanced rectal cancer
Ann. Onc., July 1, 2006; 17(7): 1173 - 1173.
[Full Text] [PDF]

Home page
 Ann OncolHome page
F. A. Calvo, F. J. Serrano, J. A. Diaz-Gonzalez, M. Gomez-Espi, E. Lozano, R. Garcia, D. de la Mata, J. A. Arranz, P. Garcia-Alfonso, G. Perez-Manga, et al.
Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation
Ann. Onc., July 1, 2006; 17(7): 1103 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Aschele, M. L. Friso, P. Del Bianco, and S. Pucciarelli
Reply to Letter to the Editor 'Weekly oxaliplatin and pre-operative radiotherapy as a new neoadjuvant therapy for locally advanced rectal cancer', by T. Watanabe et al. (Ann Oncol 2006; 17: 1173)
Ann. Onc., July 1, 2006; 17(7): 1173 - 1174.
[Full Text] [PDF]

Home page
 JCOHome page
I. Chau, G. Brown, D. Cunningham, D. Tait, A. Wotherspoon, A. R. Norman, N. Tebbutt, M. Hill, P. J. Ross, A. Massey, et al.
Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging-Defined Poor-Risk Rectal Cancer
J. Clin. Oncol., February 1, 2006; 24(4): 668 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. De Paoli, S. Chiara, G. Luppi, M. L. Friso, G. D. Beretta, S. Del Prete, L. Pasetto, M. Santantonio, E. Sarti, G. Mantello, et al.
Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study
Ann. Onc., February 1, 2006; 17(2): 246 - 251.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.